Is Dexcom (DXCM) overvalued or fairly valued?

MarketChacha shows Dexcom's valuation in context — a forward P/E of about 23.5, a price-to-book of about 9.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Dexcom (DXCM)?

Dexcom last traded at $72.23 (-3.4% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Dexcom

DXCM · NASDAQ · Healthcare · United States

$72.23-3.4%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:34 PM

Snapshot

TickerDXCM

ExchangeNASDAQ

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees11,000

HeadquartersSan Diego, United States

Market cap$27.9B

P/B9.4

Volume969.59K

Websitewww.dexcom.com

Filings tracked0

About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

1,423 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.10.10%
Vanguard Capital Management LLC6.48%
Vanguard Portfolio Management LLC4.98%
State Street Corporation4.65%
BAILLIE GIFFORD & CO4.04%
Invesco Ltd.3.54%
Alliancebernstein L.P.3.35%
Geode Capital Management, LLC3.20%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $1.3B · EPS 0.67

Est. earnings growth +10.2%

Next fiscal year

Rev $5.8B · EPS 3.08

Est. earnings growth +18.9%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$54.1152-wk range$89.98

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about DXCM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.